Because of the high cost of biologics, the authors recognized a need to provide access to evidence-based information on biosimilars for healthcare providers working with patients with inflammatory bowel disease.
A new review article discusses the data relevant to inflammatory bowel disease on biosimilars for anti-tumor necrosis factor (anti-TNF) inhibitors and urges physicians to consider anti-TNF biosimilars for patients with IBD.
The use of originator infliximab (Remicade), the first anti-TNF biologic approved in 1998, and additional anti-TNF drugs was found to improve outcomes and reduce the requirement for surgical interventions in patients with IBD compared to previous therapies. As a result, anti-TNF drugs are now the major drugs utilized for moderate to severe cases of ulcerative colitis (UC) and Crohn disease (CD), collectively known as IBD. These chronic, relapsing inflammatory conditions of the gastrointestinal tract compromise quality of life in patients and account for substantial healthcare expenditures. The proportion of patients with IBD is projected to increase, leading to increased costs.
Because of the high cost of biologics, the authors recognized a need to provide access to evidence-based information on biosimilars for healthcare providers working with patients with IBD.
Infliximab biosimilars in IBD
The most widely studied biosimilar in IBD is the infliximab biosimilar CT-P13 (Remsima), approved in 2013 in Europe and 2016 in the United States. The authors note the strengths of the evidence demonstrating equivalence, in particular a 2019 equivalence study on patients with CD that used a stricter equivalence margin than that required by regulatory agencies.
The authors acknowledge that in one switch study, the evidence on CD slightly favored remaining on the originator; furthermore, in a non-inferiority trial differences in effectiveness and immunogenicity between groups did not reach statistical significance but could potentially be clinically significant. However, they contend the evidence overall from switch studies supports the safety and effectiveness of a single switch from the originator to CT-P13.
Extrapolation of evidence from other indications
European Union patents on adalimumab expired in October 2018, and thus far, according to the authors, there have been no studies published on adalimumab biosimilars in patients with IBD.
They acknowledge physicians and patients may have concerns about biosimilars that have been investigated only in conditions other than IBD. They note that regulatory agencies encourage extrapolation to other conditions; regardless of the particular illness, the drug has the same mechanism of binding TNF-alpha, and therefore, the authors say, extrapolation is reasonable.
Physician and patient acceptance of biosimilars
The authors’ suggest physicians take an evidence-based approach to biosimilars, taking into account the cost savings, the regulatory process, the amount of evidence required for a biosimilar to gain approval, and the published evidence on effectiveness and safety of the biosimilar before preferentially prescribing the reference product.
Finally, the authors recognize that strategies to address patient concerns and prevent failures due to the nocebo effect are needed. Initial management of the patient’s expectations by physicians, nurses, pharmacists, and other providers, is essential to minimize the nocebo effect.
Reference
Al Sulais E, AlAmeel T. Biosimilars to antitumor necrosis factor agents in inflammatory bowel disease [published online January 10, 2020]. Biologics. doi:10.2147/BTT.S236433.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.